经动脉灌注健择治疗中晚期胰腺癌临床疗效观察  

Transarterial Infusion Chemotherapy of Gemcitabine for the Management of Advanced Pancreatic Carcinoma

作　　者：黄明[1] 飞勇[1] 杨银山[1] 谭骅[1] 孟芳[1] 汪永平[1] 

机构地区：[1]昆明医学院第三附属医院放射科介入室,云南昆明650118

出　　处：《华西医学》2004年第3期373-375,共3页West China Medical Journal

摘　　要：目的 :回顾性分析经动脉灌注健择 (盐酸吉西它滨 )治疗中晚期胰腺癌临床疗效。方法 :38例中晚期胰腺癌患者接受动脉灌注健择治疗 ,其中 2 8例曾行胆道支架置入术。治疗后观察肿瘤改变情况及临床受益反应 (CBR)。结果 :无CR病例 ,PR :13例 (34 2 % ) ,NC :11例 (30 6 % ) ,PD :12例 (33 3% ) ,2例无法评价。Kaplan-Meier法计算 6个月累积生存率为 6 6 7%。频数分布法计算中位生存期为 9 5个月。临床受益率为 86 1%(与文献相比P <O 0 1)。结论 :对于初治或化疗无效的病人 ,动脉灌注健择显示出良好的临床受益反应 。Objective:The effectiveness of transarterial infusion gemcitabine for the management of advanced pancreatic carcinoma was retrospectively analyzed.Methods:Gemeitabine was administered to 38 patients with advanced pancreatic carcinoma via interarterial catheter.Kamofsky performance score was(KPS)>50.Results:of the 13 patients(36.1%)obtained partial response(PR)and 11 patients(30.6%)had no chang(NC).Probability for 60 months cumulative survival rate was 66.7% and the median survival period was 9.5 months.No serious side effects was observed.Clinical benefit reponse(CBR)was 86.1%(31/36)(P<0.01).Conclusion:Transarterial infusion of gemcitabine appeared to be well tolerated and promising CBR in patients with advanced pancreatic carcinoma.

关 键 词：动脉灌注 健择 治疗 中晚期胰腺癌 盐酸吉西它滨 

分 类 号：R735.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]